Alexza Pharmaceuticals submits its NDA for Staccato loxapine to FDA Alexza Pharmaceuticals.

SOURCE Alexza Pharmaceuticals, Inc.. Alexza Pharmaceuticals submits its NDA for Staccato loxapine to FDA Alexza Pharmaceuticals, Inc. AZ-004 is an inhalation product applicant being created for the quick treatment of agitation in patients with schizophrenia or bipolar disorder. In August 2005 The IND for Staccato loxapine was filed with the FDA. AZ-004 has shipped a predictable and consistent protection and efficacy profile in treating patients with agitation, said James V. Cassella, PhD, Senior Vice President, Research and Advancement at Alexza. We believe that AZ-004, if approved, gets the potential to change the treatment practices for acute agitation, as the only product able to meet both patients’ desire for quickly and comfortably getting control, and the clinicians’ goal of rapidly and reliably calming an agitated patient.

A nationwide study conducted in 2008 verified that there is increasing patient misunderstandings regarding the countless types of healthcare providers – including physicians, technicians, nurses, doctor assistants and various other allied providers. The study further found that individuals want accurate information regarding these providers. The reality and transparency work would significantly reduce individual confusion and safeguard the general public by prohibiting the dangerous practice of some health care providers who make use of misleading terminology to misrepresent themselves or their qualifications, said David W. Parke II, MD, CEO of the American Academy of Ophthalmology. Patients ought to be assured in their healthcare decisions without needing to second-guess their suppliers’ credentials.A nationwide study conducted in 2008 verified that there is increasing patient misunderstandings regarding the countless types of healthcare providers – including physicians, technicians, nurses, doctor assistants and various other allied providers. The study further found that individuals want accurate information regarding these providers. The reality and transparency work would significantly reduce individual confusion and safeguard the general public by prohibiting the dangerous practice of some health care providers who make use of misleading terminology to misrepresent themselves or their qualifications, said David W. Parke II, MD, CEO of the American Academy of Ophthalmology. Patients ought to be assured in their healthcare decisions without needing to second-guess their suppliers’ credentials.